CAR T–Associated Cytokine Release Syndrome

Outcomes of CD19-directed CAR T-cell therapy in five individuals with multiple sclerosisПодробнее

The mechanisms of cardiotoxicity following treatment with CAR-TПодробнее

Elderly CAR-T #sciencefather #researchawards #CAR_T #CD19 #ImmunotherapyПодробнее

Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event ManagementПодробнее

CAR T cell TherapyПодробнее

Late Effects and Quality of Life after CAR T-cell TherapyПодробнее

Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety ProtocolsПодробнее

An EASIX-based predictive model for CRS and ICANS after CAR-T therapy in RRMMПодробнее

CANCER THERAPY | CAR-T Cells | Part-4 | Cytokine Release Syndrome | #cancer #facts #cancercureПодробнее

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtag...Подробнее

CAR T Cell Therapy: A Magic Bullet Ammunition in Immuno-TherapiesПодробнее

Module 2: Toxicity Assessment and Management | CRSПодробнее

Managing toxicities associated with bispecific T-cell engaging therapies in patients with myelomaПодробнее

Module 2: Toxicity Assessment and Management | Early & Late Side EffectsПодробнее

CAR-Tography: longitudinal mapping of CAR-T toxicities across B-cell malignanciesПодробнее

Immunotherapy Part IIПодробнее

Remote monitoring tool for CAR T-cell therapy patients in Canada | U of T TRP Capstone Defense 2024Подробнее

Pre-treatment biomarkers associated with toxicity and responses in R/R myeloma treated with ide-celПодробнее

CAR-T Revolution – Advancing Lymphoma Treatment with Precision & InnovationПодробнее

Strategies to Improve CAR T and NK Therapy - UH Research & Innovation DayПодробнее